Lipella Pharmaceuticals Bolsa (NASDAQ: LIPO)

Últimas noticias sobre Lipella Pharmaceuticals (NASDAQ:LIPO) Bolsa

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

Semiconductor contract manufacturer and design company Taiwan Semiconductor Mfg. Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) reported a 39.2% jump in its two-month revenue for January and February in 2025 as compared to the same period last year.
What Happened: TSM reported on Monday that its February 2025 revenue rose 43.1% to $7.911 billion or NT$260.01 billion from $5.527 billion or NT$181.648 from the same month in the last year. This was aided by the robust demand of its chips used for artificial intelligence applications worldwide. 
However, the company&#8217;s sales declined by 11.3% monthly as its January sales stood at $8.923 billion or NT$293.288.
Compared to the first two months of 2024, the sales rose by 39.2% in 2025 as the revenue increased from $12.092 billion or NT$397.433 billion to $16.835 billion or NT$553.297 billion for January and February combined.
See Also: <a href="https://www.benzinga.com/25/03/44213521/us-economic-slowdown-talk-of-the-town-says-economist-mohamed-el-erian-as-fed-chair-powell-reaffirms-growth-at-solid-pace">US Economic Slowdown &#8216;Talk Of The Town,&#8217; Says Economist Mohamed El-Erian As Fed Chair Powell Reaffirms Growth At &#8216;Solid Pace&#8217;</a>
Why It Matters: The Taiwanese company is a major supplier of U.S.-based chipmaker Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and it recently announced about $165 billion of investment in the U.S. to power the future of AI.
According to its press release, it plans to increase U.S. investment in advanced semiconductor manufacturing with three new fabs, two advanced packaging facilities, and an R&amp;D center.
Over the four years, TSMC&#8217;s investment will create 40,000 construction jobs, tens of thousands of high-tech jobs, and drive over $200 billion in U.S. economic impact over 10 years, benefiting key tech clients.
In addition to its newly announced manufacturing site in Phoenix, TSMC operates a fab in Camas, Washington, and design service centers in Austin, Texas, and San Jose, California.
Price Action: Taiwan Semiconductor&#8217;s stock on the Taipei exchange closed 0.70% lower at TWD 998 or $30.35, whereas it rose 0.71% to $177.10 in the U.S. on Friday.
The U.S. listed stock remains 12.14% lower on a year-to-date basis, however, it's up 27.39% over a year.
<a href="https://www.benzinga.com/quote/TSM/analyst-ratings">Benzinga tracks six analysts</a>&nbsp;with an average price target of $203.8&nbsp;for the stock, reflecting a "hold" rating. Estimates range widely from $89 to $255. Recent ratings from Barclays, and Needham average at $235, suggesting a potential 32.76% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/TSM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="386" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10040540/TSM-ANR-1024x386.png" alt="" class="wp-image-816047" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10040540/TSM-ANR-1024x386.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10040540/TSM-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10040540/TSM-ANR-768x290.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10040540/TSM-ANR.png 1060w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, advanced on Friday. SPY gained 0.56% to $575.92, and QQQ was up 0.74% to $491.79, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44163029/mstr-short-interest-falls-453-but-technical-analysis-exhibit-mixed-signals-is-michael-saylors-strategy-poised-for-a-bounce-back">MSTR Short Interest Falls 4.53% But Technical Analysis Reveals Mixed Signals: Is Michael Saylor&#8217;s Strategy Poised For A Bounce Back?</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

News

Markets

NVDA

TSMC Rides AI Wave: Sales Surge 39% In First 2 Months Of 2025 On Higher Demand

Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) ("Greenwave" or the "Company"), today announced that its margins have expanded significantly due to surging prices for scrap steel –&nbsp; already up 20% since early February and expected to go higher – ahead of steel and aluminum import tariffs taking effect on March 12, 2025.
&nbsp;
Prices for Scrap Steel have Surged More than 20% the Past Month and are Expected to Go Higher
Greenwave operates 13 metal recycling facilities in Virginia, North Carolina, and Ohio, providing 100% domestically-sourced scrap metal to Nucor, Sims, Cleveland-Cliffs, Georgia-Pacific, alongst other industry titans.
Unlike country-specific tariffs which are often modified, metal import tariffs significantly strengthen America's national security and are expected to remain in effect for the foreseeable future.
Fortress of Licenses: A Competitive Moat
Greenwave&nbsp;holds a portfolio of highly coveted operational licenses for the Company's metal recycling facilities.&nbsp;These licenses, often protected by grandfathered municipal codes, provide significant barriers to entry to competitors in Greenwave's tightly regulated markets.
Key highlights include:
<ul>
<li>Norfolk, VA Facility: Positioned near the largest U.S. Naval Base, Greenwave's&nbsp;Norfolk&nbsp;facility benefits from a steady influx of prime scrap metal and holds one of the only Virginia Department of Motor Vehicles automotive recycler/demolisher licenses in the city.</li>
<li>Virginia Beach, VA Facility: Greenwave operates the sole metal recycling facility in the state's largest city,&nbsp;Virginia Beach, strategically located directly across the street from NAS Oceana Master Jet Base and the region's thriving industrial core.</li>
<li>Portsmouth, VA Facility: A cost-effective hub for domestic and international shipments due to its proximity to the Port of&nbsp;Virginia, the Company's&nbsp;Portsmouth&nbsp;facility holds a license protected by grandfathered regulations.</li>
</ul>
Positioning for a Strategic Transaction Greenwave recently acquired the real estate for seven of its core facilities –&nbsp;thus&nbsp;reducing the Company's annual rent expenses by approximately&nbsp;$1.7 million,&nbsp;enhancing cashflow and positioning the Company for&nbsp;potential high-value strategic transactions.
Upcoming Growth Catalysts Greenwave is set to benefit from the 2025 opening of&nbsp;Nucor Corporation's&nbsp;state-of-the-art steelmaking facility&nbsp;in&nbsp;Lexington,&nbsp;North Carolina(1).&nbsp;The facility's staggering&nbsp;430,000-ton annual processing capacity, consisting of nearly 100% recycled materials, will significantly increase regional demand for recycled steel(1).
Greenwave stands as&nbsp;one of&nbsp;North Carolina's&nbsp;largest suppliers of recycled steel, operating five metal recycling facilities and an industry-leading American Pulverizer 60x85 shredder.&nbsp;The Company has a proven track record of supporting Nucor's operations,&nbsp;supplying its&nbsp;Hertford&nbsp;mill with steel for critical applications, including bridges, heavy equipment, and warships vital to American national security interests, including the&nbsp;$13 billion&nbsp;USS Gerald Ford aircraft carrier

GWAV

Greenwave Expands Margins as Steel Prices Jump, Boosted by Naval Scrap Supply and Nucor Demand, Eyes Tariff Windfall and Strategic Deals

<h3>Companies Reporting Before The Bell</h3>
• Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $305.85 million. 
• BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $1.15 billion. 
• UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) is estimated to report quarterly loss at $0.72 per share on revenue of $25.25 million. 
• DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is expected to report quarterly loss at $0.14 per share on revenue of $7.39 million. 
• Fennec Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $16.42 million. 
• Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) is estimated to report earnings for its first quarter. 
• Cohen &amp; Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COHN#AMEX">COHN</a>) is expected to report earnings for its fourth quarter. 
• Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $3.67 per share on revenue of $433 thousand. 
• Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) is estimated to report earnings for its fourth quarter. 
• Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $25.55 million. 
• NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is likely to report earnings for its fourth quarter. 
• Willis Lease Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) is estimated to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METCB#NASDAQ">METCB</a>) is projected to report earnings for its fourth quarter. 
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $176.04 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $215.50 million. 
• One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $239.77 million. 
• NCS Multistage Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCSM#NASDAQ">NCSM</a>) is likely to report earnings for its fourth quarter. 
• Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $1.62 million. 
• Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is projected to report earnings for its fourth quarter. 
• Douglas Elliman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $233.65 million. 
• Great Elm Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GECC#NASDAQ">GECC</a>) is expected to report quarterly earnings at $0.35 per share on revenue of $11.46 million. 
• Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $9.90 million. 
• Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is projected to report earnings for its fourth quarter. 
• Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $14.39 billion. 
• Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is likely to report quarterly loss at $0.18 per share on revenue of $43.88 million. 
• Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) is likely to report quarterly loss at $0.18 per share on revenue of $75.58 million. 
• TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $84.38 million. 
• Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $384.99 million. 
• Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) is likely to report quarterly loss at $0.07 per share on revenue of $158.36 million. 
• Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $59.40 million. 
• LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $57.34 million. 
• Seaport Entertainment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SEG#AMEX">SEG</a>) is likely to report earnings for its fourth quarter. 
• Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) is likely to report quarterly earnings at $0.77 per share on revenue of $149.37 million. 
• PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $67.73 million. 
• Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $23.78 million. 
• System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) is expected to report quarterly loss at $0.23 per share on revenue of $91.28 million. 
• Mission Produce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $272.00 million. 
• StandardAero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $1.37 billion. 
• Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $222.06 million. 
• HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $246.32 million. 
• PGIM ETF Trust PGIM Portfolio Ballast ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/PBL#BATS">PBL</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $147.18 million. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $121.19 million. 
• Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) is projected to report quarterly earnings at $6.36 per share on revenue of $1.14 billion. 
• Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) is likely to report earnings for its fourth quarter. 
• Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $296.50 million. 
• Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) is expected to report quarterly loss at $0.01 per share on revenue of $187.84 million. 
• Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.08 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ALGS

ASAN

AUNA

Mobile Infrastructure Corporation Common Stock

BEEP

BNTX

CHRS

COHN

CVGI

DOUG

DRIO

FENC

GAIA

GECC

GLRE

HSAI

LCTX

LFMD

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MYPS

NCSM

NPWR

ORCL

RAND

SARO

STKS

SUPV

TBRG

URGN

WLFC

YALA

Earnings Scheduled For March 10, 2025

The Company intends to use the net proceeds of any sales of Common Shares under the ATM Program for the production of all-electric vehicles, including BEAST school buses and EV Star commercial vehicles, as well as for product development, with the remainder, if any, for general corporate purposes.
 &nbsp;

Reported Friday, GreenPower Enters Sales Agreement With Roth Capital For $850K ATM Offering To Fund BEAST And EV Star EV Production

At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), a 29.5% difference vs. placebo (p &lt; 0.001). In the lower dose group, 36.3% of patients achieved EASI-75, a 23.4% difference vs. placebo (p &lt; 0.001).
In the higher dose group, 23.6% of patients achieved a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 24, representing a 14.9% difference vs. placebo (p &lt; 0.001). In the lower dose group, 19.1% of patients achieved this endpoint, a 10.3% difference vs. placebo (p = 0.002).
In addition, IGNITE met the endpoint of revised Investigator's Global Assessment (rIGATM) score of 0/1 with a ≥2-point reduction from baseline, a more stringent measure of efficacy than vIGA-AD 0/1. At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4% difference vs. placebo (p &lt; 0.001). In the lower dose group, 16.3% of patients achieved this endpoint, an 8.0% difference vs. placebo (p = 0.01).

AMGN

Reported Saturday, Amgen And Kyowa Kirin's Rocatinlimab Delivers Up To 42.3% EASI-75 Response At Week 24 In Phase 3 IGNITE Trial

The Company reported an operating loss of $2.1 million ($0.08 per share) versus a $3.4 million loss in the same quarter of 2023 ($0.18 per share).
The operating loss for the full year 2024 was $8.8 million ($0.35 per share) versus $18.5 million ($1.01 per share) in 2023.
CEO Thomas DeRosa noted that AppTech underwent significant organizational changes in the fourth quarter when a new investor group committed $5 million to improve the Company's operations; established voting control of the Board of Directors and replaced certain key executives including the CEO and CFO. New CFO Felipe Corrado stated "We are encouraged by the organizational and operating improvements made in the fourth quarter. We bolstered our capital position, reduced expenses and narrowed our focus solely to several potentially near-term and profitable customers."

APCX

Reported Friday, Apptech Posted Q4 Loss Of $0.08 Per Share, Up From Loss Of $0.18 Per Share YoY, Signaling Continued Progress On Cost Efficiency And Capital Reinforcement

The Trump administration is reportedly in discussions with four different groups regarding&nbsp;the sale of the Chinese short video platform, TikTok.
What Happened: On Sunday, U.S. President Donald Trump confirmed that his administration was communicating with four different groups regarding the sale of TikTok, reported Reuters. TikTok&#8217;s future has been uncertain since a Biden-administration law, that requires its owner, ByteDance, to either sell the platform on national security grounds by Apr 5 or risk a ban, came into effect on Jan 19.
President Trump, after assuming office on Jan. 20, signed an executive order aiming to postpone the law&#8217;s enforcement by 75 days. When asked if a deal on TikTok was imminent, Trump told reporters while on board Air Force One, &#8220;It could.&#8221; 
&#8220;We&#8217;re dealing with four different groups, and a lot of people want it &#8230; all four are good,&#8221; he added.
Although ByteDance has not expressed any interest in selling TikTok's U.S. operations, CEO Chew Shou Zi met with Trump at Mar-a-Lago in December and was also present at his inauguration ceremony.
SEE ALSO: <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44212362/bitcoin-ethereum-and-dogecoin-crash-as-trump-refuses-to-rule-out-recession-arthur-hayes-predicts-btc-to-retest-78000">Bitcoin, Ethereum And Dogecoin Crash As Trump Refuses To Rule Out Recession: Arthur Hayes Predicts BTC To Retest $78,000</a>
Why It Matters: The potential sale of TikTok comes amid growing tensions between the U.S. and China over data security. The uncertainty at TikTok has also attracted several potential buyers, including Frank McCourt, former owner of the Los Angeles Dodgers. McCourt&#8217;s bid for TikTok&#8217;s U.S. operations has been bolstered by the addition of Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) co-founder and venture capitalist Alexis Ohanian as a strategic adviser for Project Liberty, <a href="https://www.benzinga.com/general/social-media/25/03/44100560/reddit-co-founder-alexis-ohanian-joins-frank-mccourts-tiktok-bid-amid-competition-from-mrbeast-jesse-tinsley-and-reid-rasner">known as &#8220;The People&#8217;s Bid&#8221;</a>.  
YouTube&nbsp;star&nbsp;MrBeast and tech entrepreneur Jesse Tinsley are some of the other bidders. Notably, Trump has also suggested the name of Larry Ellison, the founder of Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>). Analysts estimate the fast-growing business&nbsp;could be worth as much&nbsp;as $50 billion.
Interestingly, Elon Musk, the owner of the X social network, has stated that he is not interested.
Trump&#8217;s comments come on the heels of TikTok <a href="https://www.benzinga.com/markets/emerging-markets/25/02/44040537/tiktok-invests-8-8-billion-in-thailand-data-centers-bypassing-us-china-tech-tensions">committing $8.8 billion </a>in data centers in Thailand over five years, bypassing US-China tech tensions.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44213521/us-economic-slowdown-talk-of-the-town-says-economist-mohamed-el-erian-as-fed-chair-powell-reaffirms-growth-at-solid-pace">US Economic Slowdown &#8216;Talk Of The Town,&#8217; Says Economist Mohamed El-Erian As Fed Chair Powell Reaffirms Growth At &#8216;Solid Pace&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

RDDT

US Courts New Buyers For TikTok As Deal Deadline Approaches: 'All Four Are Good,' Says Trump

Logility previously announced on January 24, 2025 that it had entered into a definitive agreement to be acquired by Aptean, Inc. ("Aptean") for $14.30 per share in an all-cash transaction (the "Aptean Merger Agreement"). The Logility Board of Directors has determined that the Unsolicited Proposal would reasonably be expected to lead to a superior proposal under the terms of the Aptean Merger Agreement. As a result of the Logility Board of Directors' determination, Logility may, under the terms of the Aptean Merger Agreement, engage in discussions with the unsolicited bidder based on the Unsolicited Proposal and Logility intends to do so.
The Aptean Merger Agreement remains in full force and effect, and the Logility Board of Directors reaffirms its existing recommendation that Logility's shareholders vote in favor of the transaction with Aptean.

LGTY

Reported Friday, Logility Confirms $15.00 Unsolicited Offer Under Review; Board Says Proposal May Be Superior To Aptean Agreement

<ul>
<li>Projects aim to be responsive to the energy needs of data centers by offering an abundant supply of operational power within two years</li>
<li>Projects target the provision of on-site, continuous, and scalable power generation, and securing data center uptime even in volatile market conditions</li>
<li>The partnership would involve innovative capital structuring coupled with environmental credit cash flow generation from the fuel cell platforms and coal mine methane (CMM)</li>
<li>Clean fuel cell technology can reduce the carbon footprint of data center and other high-volume electrical off-takers</li>
<li>Projects aspire to create jobs and other economic benefits focused on the Appalachian region</li>
</ul>

FCEL

Diversified, FuelCell Energy And TESIAC Form Acquisition And Development Company T Deliver Net-Zero Power For Data Centers

CONSOLIDATED NET REVENUES (UNAUDITED)
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(NT$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">44,961</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">49,444</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">39,751</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-9.1&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+13.1&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(US$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,374</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,506</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,269</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-8.8&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+8.3&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
Net revenues for ATM assembly, testing and material business are as follows:
ATM NET REVENUES (UNAUDITED)
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(NT$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">27,332</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">28,137</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">23,291</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-2.9&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+17.3&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(US$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">835</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">857</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">744</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-2.5&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+12.3&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>

ASE Technology Reported February 2025 Revenue Of $1.37B, Up 8.3% YoY; ATM Revenue Of $835M, Up 12.3% YoY

Billionaire investor Chamath Palihapitiya believes a proposed 10% cap on credit card interest rates would significantly disrupt the financial services industry while potentially benefiting consumers.
What Happened: &#8220;This would be phenomenally disruptive,&#8221; Palihapitiya wrote Sunday on X. &#8220;Would force everyone who can embrace ultra low cost rails to emerge. Incumbents would be in trouble for sure.&#8221;
Palihapitiya was responding to news that Congresswoman Anna Luna (R-FL) is working with Rep. Alexandria Cortez (D-NY) on legislation to cap credit card interest rates at 10%.
His comments come as President Donald Trump and Sen. Bernie Sanders (I-VT) have independently supported similar proposals. Sanders announced plans to introduce legislation <a href="https://www.benzinga.com/markets/equities/24/12/42737402/bernie-sanders-supports-trumps-credit-card-interest-rate-cap-at-10-amid-highest-defaults-since-2008-visa-and-mastercard-trade-in-the-red">backing Trump&#8217;s 10% cap idea</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This would be phenomenally disruptive. <a href="https://t.co/3mb8fZfyh3">https://t.co/3mb8fZfyh3</a>
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1898778255332905401?ref_src=twsrc%5Etfw">March 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I think opposite. Would force everyone who can embrace ultra low cost rails to emerge. Incumbents would be in trouble for sure.
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1898790966091489749?ref_src=twsrc%5Etfw">March 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The initiative gains significance as credit card defaults reach their highest levels since the 2008 financial crisis. U.S. credit card lenders wrote off $46 billion in seriously delinquent loan balances during the first nine months of 2024, a 50% increase year-over-year, <a href="https://www.benzinga.com/24/12/42721109/mark-cuban-once-said-credit-card-users-dont-want-to-be-rich-now-us-credit-card-defaults-have-skyrocketed-to-highest-levels-since-2008-financial-crisis">according to BankRegData</a>.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/03/44212386/stock-futures-drop-as-reverse-trump-trade-takes-holdpeter-schiff-says-market-shift-long-overdue-and-will-likely-continue-for-a-decade" target="_blank" rel="noreferrer noopener">Stock Futures Drop As ‘Reverse Trump Trade&#8217; Takes Hold—Peter Schiff Says Market Shift ‘Long Overdue&#8217; And Will Likely Continue For A Decade</a>
Why It Matters: While Palihapitiya acknowledged he &#8220;generally hate[s] price controls,&#8221; he expressed support for &#8220;ultra low cost rails in financial services.&#8221; His view contrasts with industry warnings that such caps could restrict credit access for lower-income Americans.
Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), the nation&#8217;s third-largest credit card lender, reported its credit card write-off rate increased to 6.1% in November, up from 5.2% a year ago.
The current average credit card interest rate stands at 21.5%, according to Federal Reserve data, <a href="https://www.benzinga.com/personal-finance/24/09/41024812/trumps-bold-plan-limit-credit-card-interest-rates-to-10-but-could-this-move-lead-to-dangerous-pr">more than double the proposed cap</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44212672/jamie-dimon-cashed-out-234-million-in-jpmorgan-stock-warren-buffett-stockpiled-334-billion-in-cash-weeks-later-markets-crashed-coincidence" target="_blank" rel="noreferrer noopener">Jamie Dimon Cashed Out $234 Million In JPMorgan Stock, Warren Buffett Stockpiled $334 Billion In Cash — Weeks Later, Markets Crashed. Coincidence?</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

Chamath Palihapitiya Calls Proposed 10% Credit Card Interest Rate Cap 'Disruptive' As Trump, Sanders, And Lawmakers Push For Reform

Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>), a leader in high-performance connectivity,&nbsp;today&nbsp;announced that it will display its innovative connectivity technology required for various AI applications at Embedded World 2025. Valens will display demonstrations in collaboration with a variety of companies, all offering the machine vision market cutting-edge solutions based on Valens' standard-compliant chipsets. These companies include Leopard Imaging, Acroname, Airy3D, Cherry Embedded Solutions, D3 Embedded, Fabrimex, Framos, Intel, RGo Robotics, and Teledyne e2v.

INTC

Valens Teams With Intel, Teledyne, and Others to Power Next-Gen Machine Vision Solutions, To Showcase AI-Driven Connectivity Tech at Embedded World 2025

VMAR

Vision Marine Technologies Announced The Filing Of A New Patent Application With Kennedy Lenart Spraggins, For Adaptive Control Of A Water Pump In A Marine Propulsion System

<ul>
<li>ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus</li>
<li>Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0</li>
<li>ESK-001 was generally well-tolerated at one year, with no new safety findings</li>
<li>Data further support ESK-001's potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasis
<ul>
<li>Phase 3 ONWARD program ongoing with topline data expected in Q1 2026</li>
</ul>
</li>
</ul>

ALMS

Reported Saturday, Alumis' ESK-001 Demonstrates Sustained PASI 90 And PASI 100 Responses At Week 52 In Phase 2 Psoriasis Study

<ul>
<li>Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm</li>
<li>Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD</li>
<li>Topline results from Phase 3 ICONIC-ADVANCE 1&amp;2&nbsp;studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO</li>
<li>These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO</li>
</ul>

Reported Saturday, Johnson & Johnson's Icotrokinra Achieves Complete Skin Clearance In 46% Of Patients At Week 24, Showing Potential To Redefine Psoriasis Treatment

Economist Mohamed El-Erian highlighted the risks of an economic slowdown as Federal Reserve Chairman Jerome Powell reiterated that the economy was growing at a &#8220;solid pace&#8221; during his Friday address at the University of Chicago.
What Happened: During a podcast with Forward Guidance, the chief economic advisor at Allianz, El-Erian underscored &#8220;two disturbing data&#8221; sets on the stagflation side.
This included a fall in February&#8217;s ISM Manufacturing New Orders Index, which contracted to 48.6% after expanding for three months, indicating a weakening demand and a decline in new orders compared to the previous month.
The other data set highlighted by El-Erian included February&#8217;s job report, wherein nonfarm payrolls increased by 151,000 and the unemployment rate rose to 4.1%, the highest in 3.5 years, thus inducing uncertainty in the labour market. However, &#8220;one qualification is the slip in labor force participation,&#8221; from 62.6% to 62.4%, according to him.
&#8220;So the concern that we all have, is that while growth is slowing down, companies will feel that they need to pass on the higher costs into higher prices, of course that&#8217;s why tariffs play a major role because people are worried that it won&#8217;t be a once and for all effect, it may be a repeated effect, so there&#8217;s a price level and then there&#8217;s an inflation effect,&#8221; he said.
Economic slowdown was &#8220;the talk of the town,&#8221; El-Erian said while highlighting lower oil prices, negative stock futures, lower yields, and a weaker dollar on Monday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The possibility of lower US economic growth is now the talk of the town, amplified by this weekend's remarks from high-level officials. As you would expect, the market impact so far this early morning in Asian trading includes lower oil prices (with Brent again joining WTI below… <a href="https://t.co/egyftI2GpR">pic.twitter.com/egyftI2GpR</a>
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1898950253325279263?ref_src=twsrc%5Etfw">March 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, President Donald Trump did not rule out a recession this year, acknowledging potential short-term turbulence from his economic agenda but expressing confidence in future prosperity. In a Fox News interview, he said, "I hate to predict things like that" and called the changes "very big."
See Also: <a href="https://www.benzinga.com/government/regulations/25/03/44160833/us-dollar-weakness-a-symptom-not-cause-argues-expert-as-economist-hails-devaluation-to-restore-global-growth">US Dollar Weakness A &#8216;Symptom Not Cause,&#8217; Argues Expert As Economist Hails Devaluation To &#8216;Restore Global Growth&#8217;</a>
Why It Matters: Despite the looming uncertainties and the difficulty of businesses to chart their way forward, Fed Chair Powell <a href="https://www.federalreserve.gov/newsevents/speech/powell20250307a.htm">said</a>, &#8220;The U.S. economy continues to be in a good place.&#8221;
He reaffirmed that the labor market is solid, and inflation has moved closer to the 2% longer-run goal. &#8220;At the Federal Reserve, we are intently focused on the dual-mandate goals given to us by Congress: maximum employment and stable prices,&#8221; Powell said.
Outlining the future course of action, he said that if inflation doesn&#8217;t fall to the 2% goal, the Fed will maintain policy restraint for longer and if the labor market weakens, the Fed will ease the policy accordingly.
Talking about the rate cuts, El-Erian added that he sees one cut and not three cuts in 2025 because of the persistent inflation and how the Fed is unlikely to &#8220;look through&#8221; that issue, the way they did in 2021.
Price Action: Futures of the Dow Jones slipped to 0.38%, whereas S&amp;P 500 and Nasdaq 100 declined by 0.49% and 0.61% respectively. Crude Oil WTI Futures dropped 0.51% to $66.7, the dollar index spot was down to the 103.816 level and the 10-year Treasury bonds yielded 4.29% as of 2:18 a.m., EDT.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, advanced on Friday. SPY gained 0.56% to $575.92, and QQQ was up 0.74% to $491.79, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44159401/rigetti-claims-leadership-in-quantum-computing-race-aims-to-scale-to-100-qubits-as-it-looks-to-catch-up-with-ibm-google">Rigetti Asserts &#8216;Leadership&#8217; In Quantum Computing Race, Aims To Scale To 100 Qubits As It Looks To Catch Up With IBM, Google</a></li>
</ul>
Photo courtesy: Federal Reserve

Government

Federal Reserve

US Economic Slowdown 'Talk Of The Town,' Says Economist Mohamed El-Erian As Fed Chair Powell Reaffirms Growth At 'Solid Pace'

<ul>
<li>Low disease activity was observed after a mean duration of 80 consecutive days off-treatment following success with VTAMA cream, with a mean weekly Peak Pruritus Numerical Rating Scale (PP-NRS) score of 2.9 at the end of the treatment-free interval</li>
<li>Data presented as late breaker at 2025 American Academy of Dermatology (AAD) Annual Meeting</li>
</ul>

Reported Saturday, Organon's VTAMA Phase 3 Data Shows 84% Of Patients Maintained Mild Disease After 80-Day Off-Treatment Interval In Adults And Children 2+

<ul>
<li>Significantly more patients treated with Sotyktu achieved ACR and PASI response rates and had greater improvements in patient-reported quality of life compared with placebo at Week 16</li>
<li>Sotyktu was well-tolerated in comparison with placebo and apremilast, demonstrating safety consistent with its established clinical profile</li>
</ul>

Reported Saturday, Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Showing Sotyktu Superior To Placebo In Psoriatic Arthritis

<ul>
<li>Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study</li>
<li>Topline results from Phase 3 ICONIC-ADVANCE 1&amp;2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO</li>
<li>Results pave the way to initiate the first-ever head-to-head study (ICONIC-ASCEND) seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe PsO</li>
</ul>

PTGX

Reported Saturday, Protagonist Reports Icotrokinra Achieved IGA 0/1 In 74% Of Patients At Week 24 With Favorable Safety Profile

Four Canadian stores of&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) have been suspected of exploiting the country&#8217;s EV rebate program. The stores are said to have sold an average of 30&nbsp;cars per hour over three days, claiming&nbsp;over 50% of the&nbsp;remaining rebate funds.
What Happened: Four Tesla stores in Canada managed to sell an average of 30 cars per hour, amounting to 120 cars per hour across all four locations, as <a href="https://www.thestar.com/news/canada/tesla-gamed-the-system-canadian-auto-dealers-stiffed-millions-when-u-s-giant-rushed-to/article_6d1025c6-fa0a-11ef-b780-a73277202cb2.html">reported </a>by the Toronto Star on Friday. 
This sales boom lasted for three consecutive days, even during hours when the stores were supposedly closed. Reportedly, a total of 8,653 cars were sold during the final 72 hours of the EV rebate program, also known as the iZEV Program.
Consequently, the Elon Musk-led company applied&nbsp;for C$43.1 million ($30 million) in&nbsp;rebates, which is over&nbsp;half of the remaining C$71.8&nbsp;million ($50 million) allocated for EV&nbsp;rebates.
The iZEV rebate program provided incentives ranging from C$2,500 ($1740.29) to C$5,000 ($3480.57) for purchasing electric vehicles and plug-in hybrids. Dealerships applied the rebate directly to the purchase price, anticipating reimbursement from the government.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
As a result of the incident, the rival brands haven&#8217;t been able to access the EV credits as Tesla claimed more than half of them. The Canadian Automobile Dealers Association (CADA), has received rebate claims for 2,295 electric vehicles from 226 dealers who are yet to receive the reimbursement, resulting in a collective shortfall of C$10 million.
CADA&#8217;s spokesperson, Huw Williams, told the Toronto Star, "Somehow, Tesla gamed the system. What we can't figure out is how this could have happened without setting off alarm bells."
Notably, Transport Canada, the body which oversees the iZEV rebate program, has not clarified whether any wrongdoing took place. It also stated that there is no restriction preventing Tesla from submitting rebate paperwork in bulk after delivering sold cars.
SEE ALSO: <a href="https://www.benzinga.com/news/25/03/44211240/warren-buffett-on-debt-and-donald-trumps-money-moves-trump-never-went-right">Warren Buffett on Debt and Donald Trump&#8217;s Money Moves: Trump &#8216;Never Went Right&#8217;</a>
Why It Matters: Tesla has been struggling in Canada, wherein thousands of Canadians have even signed a petition for revoking Musk&#8217;s Canadian citizenship. According to&nbsp;data from shop4tesla.com, the EV maker&#8217;s sales in Canada have dropped by approximately 70% between December 2024 and January 2025.
This surge in sales comes on the heels of Tesla&#8217;s recent offer of lifetime free supercharging for new Foundation Series Cybertruck purchases in Canada. Tesla <a href="https://www.benzinga.com/tech/25/03/44160193/tesla-offers-lifetime-free-supercharging-on-foundation-series-cybertruck-purchases-in-canada-mexico">announced this offer </a>to make the expensive truck more appealing to customers. The offer, valid for orders placed on or after March 5, lasts for the duration of the customer's ownership of the vehicle and is non-transferable.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/03/44212993/palantir-ceo-alex-karp-meets-hyundai-vice-chair-to-enhance-ai-shipyard-defense-collaboration-amid-trumps-call-for-us-shipbuilding-revival">Palantir CEO Alex Karp Meets Hyundai Vice Chair to Enhance AI Shipyard, Defense Collaboration Amid Trump&#8217;s Call for US Shipbuilding Revival</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

Lipella Pharmaceuticals

Noticias

Últimas noticias sobre Lipella Pharmaceuticals (NASDAQ:LIPO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL